Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilomilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4A known ✓ | P27815 | 19/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 19/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilomilast SCHEMBL27516 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL27515 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL13777301 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL26372 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL6904030 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL29107422 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL7130621 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL7130626 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL7124080 | 0.97 | PDE4B (0.94) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL28381093 | 0.96 | PDE4B (0.92) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1250313-B1 | MONOHYDRATE OF CIS-LITHIUM-CYANO-4- 3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL|CYCLOHEXANECARBOXYLATE | SMITHKLINE BEECHAM CORP (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1250313-A4 | MONOHYDRATE OF CIS-LITHIUM-CYANO-4- 3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANECARBOXYLATE | SMITHKLINE BEECHAM CORP (US) | 2005-09-21 | — | — | EP | disclosed |
| US-6699903-B2 | HYDRATION OF THE ANHYDROUS LITHIUM SALT WITH ACETONITRILE AND WATER; PHOSPHODIESTERASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2004-03-02 | — | — | US | disclosed |
| US-20030032670-A1 | Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylate | GLAXOSMITHKLINE LLC | 2003-02-13 | — | — | US | disclosed |
| EP-1250313-A1 | MONOHYDRATE OF CIS-LITHIUM-CYANO-4- 3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANECARBOXYLATE | SmithKline Beecham Corporation (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001055094-A1 | MONOHYDRATE OF CIS-LITHIUM-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANECARBOXYLATE | SMITHKLINE BEECHAM CORPORATION (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032670-A1 | Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylate | CA3, CLIC4, CA4 | PDE4B 2860/4885PDE4A 2704/4885PDE4C 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.